Enzyme-Activated Cross-Linking Compounds for Stable Nanostructures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds and methods to cross-link nanostructures under physiological conditions for bioconjugation applications, as existing methods are limited.
Innovation Solution
Development of cross-linking compounds with specific structures (Formulas IA, IB, II, III, IV, and V) that can react enzymatically under physiological conditions, incorporating protecting groups, linkers, and functional groups to form stable cross-linked nanostructures for bioconjugation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cross-linking methods are used under physiological conditions, then cross-linking can occur, but the stability and reliability of the cross-linked nanostructures are insufficient for bioconjugation applications
Solution Approach 1:
The patent employs parameter changes by utilizing enzyme-specific cleavage of protecting groups (PG) under physiological conditions. The cross-linking reaction is triggered by changing the chemical state from protected to deprotected form through enzymatic action, enabling reliable cross-linking in biological environments where previous methods failed.
Solution Approach 2:
The patent introduces enzyme-labile protecting groups as intermediaries between the cross-linking agent and the target nanostructures. These PG groups act as mediators that prevent premature cross-linking while enabling controlled activation by specific enzymes, thereby improving reliability without complicating the manufacturing process.
2Adaptability or versatility
If cross-linking compounds are designed with multiple functional groups and protecting groups, then bioconjugation capability is enhanced, but the complexity of the compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the cross-linking compound into distinct functional modules: a cross-linking core (Formula IA), multiple enzyme-labile protecting groups (PG), various linkers (L1, L2, L3), and bioconjugatable groups (Z). This modular segmentation allows independent optimization of each function while maintaining overall versatility for different bioconjugation applications.
Solution Approach 2:
The patent achieves universality by designing a platform compound (Formula IA) that can accommodate multiple types of protecting groups, linkers, and bioconjugatable groups. This multi-functional design enables the same core structure to be adapted for various bioconjugation applications, enhancing versatility without proportionally increasing complexity.
3Ease of operation
If enzyme-labile protecting groups are used to enable physiological cross-linking, then in vivo applicability is improved, but the duration of action and control precision become more challenging
Solution Approach 1:
The patent uses enzyme-labile protecting groups as intermediaries that provide temporal control over cross-linking activation. The specific enzyme-substrate recognition ensures that cross-linking occurs only when and where the target enzyme is present, improving in vivo applicability while maintaining control precision through biological specificity.
Solution Approach 2:
The patent implements self-service by designing compounds where the protecting groups are automatically cleaved by endogenous enzymes at the target site. This self-activating mechanism eliminates the need for external activation systems, simplifying in vivo operation while maintaining precise spatial and temporal control through enzyme specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the formation of stable cross-linked nanostructures suitable for bioconjugation, facilitating targeted delivery and detection of cells, tissues, and agents, as well as therapeutic applications.
Implementation Method 1
each PG is a protecting group and each protecting group is independently an enzyme labile group (e.g., a glycosyl group, glucoside, glucuronide, galactosyl, phosphate (e.g., a phosphoester group) group, sulfoester group, β-lactam, phosphoramidate, group that is labile to peroxidases, and/or a self-immolative linker)
Data Source
AI summary
Compounds of Formula IA, IB, II, III, IV, and/or V are described herein along with their methods of use. A compound of the present invention may cross-link under physiological conditions and/or in vivo.